Japanese Leisure Stock News

TSE:7389
TSE:7389Banks

A Look At Aichi Financial Group (TSE:7389) Valuation After Governance And Operating Reorganization Plans

Why Aichi Financial Group Stock Is Back in Focus After Its Governance Shakeup Aichi Financial Group (TSE:7389) has moved into the spotlight after its board approved a broad reorganization of compliance, risk, sales, and markets functions, alongside significant board and executive lineup changes. These shifts, which start from April 2026 and run through June 2026, are designed to tighten integration between Aichi Financial Group, Aichi Bank, and the group leasing subsidiary while reshaping...
TSE:6471
TSE:6471Machinery

NSK (TSE:6471) Valuation Check After Recent Share Pullback And Restructuring Profit Targets

Event context and recent share performance NSK (TSE:6471) shares have come under pressure recently, with a 1 day return of 1.39% and a 6% decline over the past week, adding to a roughly 9.8% pullback over the past month. See our latest analysis for NSK. While the recent 30 day share price return of a 9.8% decline suggests fading short term momentum, the 90 day share price return of 21.86% and 1 year total shareholder return of 87.69% point to a much stronger longer term picture. If NSK’s...
TSE:8473
TSE:8473Capital Markets

A Look At SBI Holdings (TSE:8473) Valuation After Dividend Hike And ¥50b Share Buyback

Why SBI Holdings (TSE:8473) just moved its dividend goalposts SBI Holdings (TSE:8473) has raised its year end dividend forecast to ¥75 per share and highlighted a completed ¥50b share buyback, following a board decision tied to profits in its Financial Services Business. See our latest analysis for SBI Holdings. The updated dividend and completed ¥50b buyback come after a weaker run in the share price, with a 30 day share price return of 17.6% and a year to date return of 14.26%. This...
TSE:5844
TSE:5844Banks

Kyoto Financial Group (TSE:5844) Valuation After Earnings Upgrade Special Dividend And Expanded Buyback

Kyoto Financial Group Inc (TSE:5844) has drawn investor attention after sharply raising its earnings guidance, funded by large gains on equity sales, and pairing that move with a special dividend and expanded share buyback plan. See our latest analysis for Kyoto Financial GroupInc. The flurry of guidance upgrades, special dividend plans and the expanded buyback has coincided with strong recent momentum, with a 30 day share price return of 15.21% and a 1 year total shareholder return of...
TSE:4967
TSE:4967Personal Products

Assessing Kobayashi Pharmaceutical (TSE:4967) Valuation After Oasis Management’s Governance Challenge

Governance dispute focuses attention on Kobayashi Pharmaceutical Oasis Management’s public campaign against Kobayashi Pharmaceutical (TSE:4967) and its move to a Company with an Audit and Supervisory Committee has pushed the company’s governance structure and board oversight firmly into the spotlight for shareholders. See our latest analysis for Kobayashi Pharmaceutical. The governance dispute has arrived after a period where the 90 day share price return of 7.41% contrasts with a weaker 3...
TSE:7013
TSE:7013Machinery

Assessing IHI (TSE:7013) Valuation After Recent Share Price Pullback And Long Term Rerating

Why IHI (TSE:7013) is on investors’ radar today IHI (TSE:7013) has recently drawn attention after a period of mixed share performance, with a negative month but a strong past 3 months and 1 year total return. This has prompted fresh questions about how its current valuation lines up with fundamentals. See our latest analysis for IHI. At a share price of ¥3,734.0, IHI has recently seen a 10.02% 1 month share price decline, following a strong 27.42% 3 month share price return and a very large 5...
TSE:4528
TSE:4528Pharmaceuticals

Ono Pharmaceutical (TSE:4528) Deepens AI-Driven R&D With Congruence Deal – A Strategic Shift?

Earlier in March 2026, Ono Pharmaceutical Co., Ltd. and Congruence Therapeutics expanded their drug discovery collaboration to cover neurology and immunology, giving Ono exclusive worldwide option rights over any resulting small molecule candidates and tying Congruence’s economics to upfront, milestone and tiered royalty payments. This move extends Ono’s use of Congruence’s Revenir computational platform beyond oncology into areas of significant unmet medical need, potentially reshaping the...
TSE:3774
TSE:3774Telecom

Assessing Internet Initiative Japan (TSE:3774) Valuation After Launch Of New Internal Security Assessment Service

Internet Initiative Japan (TSE:3774) has introduced a new Internal Vulnerability Assessment service within its Safous Security Assessment offering, giving customers broader visibility into security risks across internal networks and distributed sites. See our latest analysis for Internet Initiative Japan. The new security service arrives as Internet Initiative Japan’s share price trades at ¥2,333.5, with a 7 day share price return of 3.55% and a 30 day share price return of 4.97%. This...
TSE:8306
TSE:8306Banks

New MUFG Leaders May Steer Capital Priorities For Undervalued Shares

Mitsubishi UFJ Financial Group (TSE:8306) has announced significant leadership changes at the senior executive level. Takuya Tanaka has been appointed Senior Managing Corporate Executive with responsibilities linked to commercial banking and wealth management. Yoshiaki Ueno has been appointed Managing Corporate Executive with a focus on corporate planning and group level management. These appointments mark a reshuffling of top roles that could influence group wide priorities and capital...
TSE:3480
TSE:3480Real Estate

J.S.B.Co.Ltd (TSE:3480) Swing Back To Q1 Profit Tests Volatility Narrative

J.S.B.Co.Ltd (TSE:3480) opened Q1 2026 with revenue of ¥16.8b and basic EPS of ¥18.13, alongside trailing twelve month EPS of ¥285.67 on revenue of ¥77.6b. Over recent quarters the company has seen quarterly revenue move between ¥15.3b and ¥27.0b while basic EPS has ranged from a loss of ¥24.20 per share to a profit of ¥267.87 per share, giving investors a wide set of earnings outcomes to weigh against the current print. With trailing net profit margin at 7.8% compared with 7.3% a year...
TSE:2929
TSE:2929Biotechs

Pharma Foods International Q2 Profit Challenges Bearish Earnings Narratives

Pharma Foods International (TSE:2929) has just posted its Q2 2026 numbers, with revenue of ¥16.7 billion and basic EPS of ¥2.31, alongside net income of ¥67 million. Over the last six quarters, the company has seen quarterly revenue move between ¥14.6 billion and ¥18.4 billion. Basic EPS has swung from a loss of ¥65.50 to a gain of ¥51.59 before landing at the latest ¥2.31 print, which puts the spotlight firmly on how much of that top line is actually flowing through to shareholders. For...
TSE:3193
TSE:3193Hospitality

Eternal Hospitality GroupLtd (TSE:3193) EPS Slide To ¥25 Challenges Bullish Growth Narratives

Eternal Hospitality GroupLtd (TSE:3193) has posted its Q2 2026 numbers with revenue of ¥12.8 billion and basic EPS of ¥25.03, alongside net income of ¥288.78 million, giving investors a clear snapshot of mid year trading. The company has seen quarterly revenue move from ¥11.2 billion in Q2 2025 to ¥12.8 billion in Q2 2026, while basic EPS shifted from ¥28.28 to ¥25.03 over the same period, and investors will be weighing these trends against the latest margin picture and how efficiently those...
TSE:3159
TSE:3159Specialty Retail

Maruzen CHI Holdings (TSE:3159) Margin Compression To 1.8% Tests Bullish Narratives

Maruzen CHI HoldingsLtd (TSE:3159) has wrapped up FY 2026 with fourth quarter revenue of ¥43.3b and basic EPS of ¥2.47, rounding out a year where quarterly revenue ranged between ¥43.1b and ¥49.3b and EPS moved from ¥17.29 in Q1 to ¥2.47 in Q4. Across the latest trailing twelve months, revenue came in at ¥185.1b with basic EPS of ¥36.03, which may encourage investors to focus less on headline growth stories and more on how the business is converting that top line into earnings. With trailing...
TSE:4996
TSE:4996Chemicals

Kumiai Chemical Industry Q1 Margin Compression Challenges Bullish Earnings Growth Narrative

Kumiai Chemical Industry (TSE:4996) has opened fiscal 2026 with Q1 revenue of ¥46,707 million and basic EPS of ¥32.74, setting a fresh reference point after a volatile run of quarterly earnings. The company has seen revenue move from ¥43,381 million in Q1 2025 to ¥46,707 million in Q1 2026, while basic EPS shifted from ¥33.25 to ¥32.74 over the same periods. This gives investors a clean snapshot of the top and bottom line as they weigh how a thinner 2.5% trailing net margin and that prior...
TSE:9697
TSE:9697Entertainment

Did Capcom’s (TSE:9697) Resident Evil PC Tie-in and Leadership Shuffle Just Reframe Its IP Strategy?

GIGABYTE recently announced a collaboration with Capcom to promote the upcoming Resident Evil Requiem game through a themed custom PC giveaway and bundled monitor-game offers, while Capcom’s board approved director changes and new management roles effective April 1, 2026. Together, the gaming hardware tie-in and leadership reshuffle highlight how Capcom is leaning on flagship IP while refining its internal business focus. We’ll now examine how the Resident Evil Requiem collaboration with...
TSE:9984
TSE:9984Wireless Telecom

Reassessing SoftBank Group (TSE:9984) After Recent Share Price Slide And AI Narrative Shifts

Wondering whether SoftBank Group's current share price actually lines up with its underlying value? This article walks through the numbers so you can see how the market is pricing the story. The stock closed at ¥3,578 after an 8.9% decline over the last 7 days, a 24.0% drop over 30 days and a 22.5% fall year to date, while the 1 year return sits at 83.4% and the 3 year return is very large at about 3x. These swings have come as SoftBank Group continues to be closely watched as a major...
TSE:6702
TSE:6702IT

Fujitsu’s AI Infrastructure Alliance With Arrcus and 1Finity Could Be A Game Changer For Fujitsu (TSE:6702)

In early March 2026, Arrcus announced a collaboration with Fujitsu and 1Finity to combine FUJITSU-MONAKA Arm-based CPUs, ArcOS software-defined networking, and high-speed optical interconnects into a secure, energy-efficient infrastructure for distributed AI workloads from edge inference to large-scale training. This partnership highlights Fujitsu’s push to align compute, networking, and optical transport for emerging Physical and enterprise AI use cases such as smart factories, robotics,...
TSE:8002
TSE:8002Trade Distributors

Assessing Marubeni’s Valuation As The Branford Castle Partnership Expands Global Investment Reach

Why Marubeni’s Branford Castle deal matters for shareholders Marubeni (TSE:8002) has drawn investor attention after committing capital to Branford Castle Partners’ new flagship fund and agreeing to work alongside the firm to source and support global investment opportunities. See our latest analysis for Marubeni. The Branford Castle agreement lands while Marubeni’s share price sits at ¥5,591, with a 1 day share price return of 4.02% and 7 day return of 3.86%. However, the 30 day share price...
TSE:6645
TSE:6645Electronic

Omron’s SF2030 Plan Targets Data Growth In Automation And Healthcare

OMRON (TSE:6645) has released its SF2030 2nd Stage medium term plan, outlining a broad shift toward data driven operations. The plan highlights increased focus on industrial automation, healthcare, and targeted growth in Europe. This roadmap sets out multi year priorities for redirecting investment and reshaping the company’s business mix. OMRON, trading at ¥4,532.0, enters this new phase after a mixed share price record, with a 13.4% return year to date and a 3.5% return over 1 year,...
TSE:4118
TSE:4118Chemicals

Does Kaneka’s Toro 88 Superbore Catheter Launch Deepen Its Neurovascular Ambitions For Kaneka (TSE:4118)?

Toro Neurovascular previously announced that the U.S. FDA had granted 510(k) clearance for its Toro 88 Superbore Catheter, with Kaneka Medical America LLC leading the U.S. commercial launch following the device’s first successful clinical use by Dr. Satoshi Tateshima. This launch underscores Kaneka’s deeper involvement in the neurovascular device market, pairing Toro’s catheter technology with Kaneka’s established U.S. sales and clinical support network. We’ll now examine how Kaneka’s role...
TSE:8058
TSE:8058Trade Distributors

How Frontier Lithium’s PAK MOU Could Shape Mitsubishi’s North American Battery Role (TSE:8058)

In March 2026, Frontier Lithium announced it had signed a non-binding Memorandum of Understanding with Panasonic Energy and Mitsubishi to explore lithium hydroxide procurement and broader collaboration around the PAK Lithium Project in Ontario, aimed at supplying North America’s electric vehicle battery supply chain from 2030. A key insight is that Mitsubishi’s existing joint venture role in the PAK Lithium Project now sits within a wider potential offtake and technical cooperation framework...
TSE:6920
TSE:6920Semiconductor

Lasertec (TSE:6920) Is Up 12.7% After Surprise Surge In Chip Inspection Tool Orders – What's Changed

In March 2026, Lasertec drew heightened attention after reports of stronger-than-expected order momentum for its semiconductor inspection and wafer metrology equipment, following a sharp sector-wide selloff tied to inflation concerns. This sequence of macro-driven weakness followed by renewed product-focused interest highlights how quickly sentiment can swing around Lasertec’s core inspection business. We’ll now examine how this stronger-than-expected order momentum for semiconductor...
TSE:3407
TSE:3407Chemicals

Is Asahi Kasei (TSE:3407) Still Attractive After Its Strong Multi Year Share Price Run

If you are wondering whether Asahi Kasei is still good value after its recent run, you are not alone. The key question now is how the current share price lines up with the underlying business. The stock closed at ¥1,616.5, with returns of 13.8% year to date, 60.5% over 1 year, 94.7% over 3 years and 38.5% over 5 years, although it has seen a 5.6% decline over the last 7 days and a 6.9% decline over the last 30 days. Recent news coverage around Asahi Kasei has focused on its position in the...
TSE:4151
TSE:4151Pharmaceuticals

Kyowa Kirin (TSE:4151) Valuation Check After Rocatinlimab Trials Are Halted Over Safety Concerns

Kyowa Kirin (TSE:4151) has moved to discontinue all clinical trials of rocatinlimab after a planned safety review highlighted malignancy concerns linked to OX40 pathway modulation, including confirmed and suspected Kaposi’s sarcoma cases. See our latest analysis for Kyowa Kirin. At a share price of ¥2,339, Kyowa Kirin has seen a 1-day share price return of 1.56% and a 7-day gain of 3.89%, compared with a weaker 30-day share price return of a 10.11% decline and a year-to-date share price...